Day One | Advancing Targeted Therapies | Publications

November 2022

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

van Tilburg CM, Jones DTW, Schmidt R, Avula S, Schouten-van Meeteren A, Sehested A Opocher E, Hernáiz Driever P, Witt R, Ziegler DS, Blackman SC, Zhao X,Tsao L-P,Manley P,Cox MC, Hargrave D, Witt O 2022 Society for Neuro-Oncology – Annual Meeting 2022 SNO Annual Meeting: Abstract CTNI-30

June 2022

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors

Landi D, Ziegler DS, Franson AT, Baxter PA, Leary SES, Larouche V, Waanders AJ, van der Lugt J, McCowage G, Jabado N, Cornelio I, Blackman SC, Da Costa D, Cox MC, Witt O, Kilburn L, Hansford JR. ASCO Annual Meeting 2022: Abstract TPS10062

November 2021

Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion

Offer K, McGuire M, Venetsanakos E, Blackman S, Song K, Goldfischer M, Cox M 2021 Connective Tissue Oncology Society Annual Meeting

October 2021

FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion

Mehmi I, Lourdes L, Cornelio I, Blackman S, Barry E, Drexel M, Kondo A, Kummar S 18th International Congress of the Society for Melanoma Research

October 2021

Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma

Medina T, Barry E, Raju S, Blackman S, Gonzalez R 18th International Congress of the Society for Melanoma Research

« Previous 1 2 3 4

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No